Introduction {#S1}
============

Colitis-associated colorectal cancers are etiologically and molecularly distinct from familial adenomatous polyposis coli-associated colorectal cancer, hereditary non-polyposis coli colorectal cancer, and sporadic colorectal cancer. The malignancy occurs in individuals suffering from ulcerative colitis or Crohn's disease (collectively, inflammatory bowel disease) with an incidence that is proportional to duration of the disease. The neoplastic progression of disease-striken colonic epithelium is believed to be driven by the chronic inflammatory microenvironment, which promotes the progressive genomic instability of colonic epithelial stem cells by inducing sustained hyperproliferation (regenerative atypia) and by the continuous presence of high local concentrations of DNA damaging agents, such as reactive oxygen species (reviewed in ([@R10], [@R55])).

While there is considerable debate about the relative importance of the specific factors that contribute to the development of inflammatory bowel disease, there is a consensus that the disease represents an inappropriate immune response to the commensal microbiota in genetically predisposed individuals (reviewed in ([@R24], [@R55], [@R58], [@R71], [@R73])). In this regard, the contribution of aberrant inflammatory circuits to the development of inflammatory bowel disease has been clearly established by genetic analysis, including genome-wide association studies, that have linked loss of function mutations or polymorphisms in genes encoding interleukins, interleukin receptors, chemokine receptors, nucleotide-binding oligomerization domain (NOD)-like receptors, toll-like receptor 4, intelectins, and prostaglandin receptors to ulcerative colitis, to Crohn's disease or to both. Further support for a principal role of derailed inflammatory circuits is gained from the spontaneous inflammatory bowel disease observed in mice deficient in a variety of immune effectors (reviewed in ([@R24], [@R55], [@R58], [@R71], [@R73])). Much less explored is the importance of individual components of the intestinal epithelial barrier in preventing inflammatory bowel disease, and the potential contribution of intrinsic intestinal epithelial barrier defects to the development of the syndrome. The clearest indication of the potential importance of primary barrier integrity comes from studies of mice with germline ablation of *Muc2* encoding the major mucin that shields the intestinal epithelium from direct contact with the microbiota. These mice develop colitis, which may progress to colon adenocarcinomas in older animals ([@R72]). Additional evidence has been obtained from transgenic mice with intestinal epithelial-specific overexpression of myosin light chain kinase, which display decreased barrier function and increased immune activation, although an inflammatory bowel-like syndrome did not emerge in the absence of additional immunological challenges ([@R63]).

Matriptase is a member of the recently established family of type II transmembrane serine proteases that is encoded by the *Suppression of Tumorigenicity-14* (*ST14*) gene ([@R7], [@R27], [@R30], [@R67], [@R69]). *ST14* was originally proposed to be a colon cancer tumor suppressor gene, due to its specific down-regulation in adenocarcinomas of the colon ([@R75]). Matriptase is expressed in multiple epithelia of the integumental, gastrointestinal, and urogenital systems, where it has pleiotropic functions in the differentiation or homeostasis of both simple and stratified epithelia, at least in part through the proteolytic activation of the epithelial sodium channel activator, prostasin/PRSS8 ([@R65]). In simple epithelium of the gastrointestinal tract, a principal function of matriptase is to promote the formation of a paracellular permeability barrier, possibly through the posttranslational regulation of the composition of claudins that are incorporated into the epithelial tight junction complex of differentiating intestinal epithelial cells ([@R8], [@R33]).

Through lineage-specific loss of function analysis in mice we now have examined the role of *St14* as a tumor suppressor gene. Interestingly, we found that the selective ablation of *St14* from intestinal epithelium results in the formation of adenocarcinoma of the colon with very early onset and high penetrance. Neoplastic progression occurs in the absence of exposure of animals to carcinogens or tumor promoting agents, is preceded by chronic colonic inflammation that resembles human inflammatory bowel disease, and can be suppressed by aggressive antibiotics treatment. The study demonstrates that inflammation-associated colon carcinogenesis can be initiated solely by intrinsic paracellular permeability barrier perturbations, and establishes that *St14* is a critical tumor suppressor gene in the mouse gastrointestinal tract.

Results {#S2}
=======

Meta-analysis of transcriptomes shows decreased expression of ST14 in human colon adenomas and adenocarcinomas {#S3}
--------------------------------------------------------------------------------------------------------------

We first performed *in silico* data mining of the Oncomine microarray database ([@R52]) to corroborate the initial report of reduced *ST14* expression in human colon cancer ([@R75]) ([Figure 1](#F1){ref-type="fig"}). Interestingly, *ST14* was significantly downregulated compared to normal colon in seven of the fourteen published studies listed in the database (studies A and C--H), whereas six studies showed no change (studies B and J--N) and a single study (study I) found *ST14* to be upregulated ([Figure 1](#F1){ref-type="fig"} and [Supplementary Table 1](#SD4){ref-type="supplementary-material"}). Of the fourteen studies, study A, which compared gene expression in colorectal dysplastic adenomatous polyps to normal colonic epithelium, was conducted using laser capture microdissected tissue (*ST14* downregulation, P \< 0.0006) ([@R18]), and therefore provided the most reliable estimate of *ST14* expression in normal and dysplastic colonic epithelium.

St14-ablated colonic epithelium undergoes rapid and spontaneous malignant transformation {#S4}
----------------------------------------------------------------------------------------

To specifically explore the functional consequences of intestinal loss of *St14* on colon carcinogenesis, we interbred mice carrying an *St14^LoxP^* allele ([@R33]) with mice carrying an *St14* null allele (*St14^−^*) and mice carrying a *Cre* transgene under the control of the intestinal-specific villin promoter (*villin-Cre^+^*) ([@R36]). This resulted in the generation of *villin-Cre^+/0^*;*St14^LoxP/−^* mice (hereafter termed *St14^−^* mice) and their associated littermates *villin-Cre^+/0^*;*St14^LoxP/+^*, *villin-Cre^0^*;*St14^LoxP/−^*, and *villin-Cre^0^*;*St14^LoxP/+^* (hereafter termed *St14^+^* mice). As reported recently ([@R33]), this strategy resulted in the efficient deletion of matriptase from the entire intestinal tract, as shown by the loss of matriptase immunoreactivity in colon (compare [Supplementary Figure 1a and b](#SD1){ref-type="supplementary-material"}) and small intestine (compare [Supplementary Figure 1c and d](#SD1){ref-type="supplementary-material"}), and by highly diminished *St14* transcript abundance ([Supplementary Figure 1e](#SD1){ref-type="supplementary-material"}). *St14^−^* mice were outwardly unremarkable at birth, but displayed significant growth retardation after weaning ([Supplementary Figure 1f](#SD1){ref-type="supplementary-material"}). Examination of prospective cohorts of *St14^−^* mice and their associated littermate controls revealed that intestinal *St14* ablation greatly diminished life span ([Supplementary Figure 1g](#SD1){ref-type="supplementary-material"}).

Unexpectedly, histological analysis of moribund *St14^−^* mice revealed the presence of invasive adenocarcinoma of the colon in 8 of 24 (33%) of *St14^−^* mice examined at four to 18 weeks of age ([Table 1](#T1){ref-type="table"}, [Figure 2a, b, and d](#F2){ref-type="fig"}) and dysplastic colonic epithelium (regenerative atypia) in the remaining 16 mice ([Table 1](#T1){ref-type="table"} and [Figure 2d](#F2){ref-type="fig"}). Remarkably, in light of the fact that these mice were not carcinogen treated or exposed to other insults to the intestinal tract, adenocarcinoma could be found in mice less than five weeks of age ([Table 1](#T1){ref-type="table"}). All adenocarcinomas had progressed to invade the muscularis mucosae underlying the colonic epithelium and the subadjacent muscularis externa ([Figure 2a and b](#F2){ref-type="fig"}). Furthermore, in six of eight (75%) adenocarcinomas examined, the tumor cells had infiltrated the lymphatic vasculature, as revealed by combined immunohistochemical staining with pan-keratin antibodies and antibodies against the lymphatic endothelial marker, LYVE-1 ([Table 1](#T1){ref-type="table"} and [Figure 2c and d](#F2){ref-type="fig"}). The tumors displayed many hallmarks of human colitis-associated colon cancer, including activation of β-catenin ([Figure 3a and a′](#F3){ref-type="fig"}), dysorganized basement membrane deposition ([Figure 3b and b′](#F3){ref-type="fig"}), fibrosis ([Figure 3c and c′](#F3){ref-type="fig"}), severe dysplasia with abundant atypical mitosis ([Figure 3d](#F3){ref-type="fig"}), epithelial hyperproliferation ([Figure 4a and a′](#F4){ref-type="fig"}), loss of terminal differentiation ([Figure 4b and b′](#F4){ref-type="fig"}), and chronic inflammatory cell infiltrates ([Figure 4c and c′, d and d′](#F4){ref-type="fig"}). Importantly, the small intestine was histologically unremarkable in all mice examined (data not shown), although *St14* was efficiently ablated also from this tissue ([Supplementary Figure 1d and e](#SD1){ref-type="supplementary-material"}). Taken together, these data show that *St14* is a critical tissue-specific tumor suppressor gene in the mouse intestine that suppresses the formation of early, invasive adenocarcinomas of the colon.

Impaired barrier function in St14-ablated colon {#S5}
-----------------------------------------------

We have previously shown that either reduced matriptase expression or global postnatal ablation of matriptase from all tissues results in impaired intestinal barrier function ([@R8], [@R33]), suggesting that this would also be a feature of mice with intestinal epithelial-specific embryonic deletion of matriptase. To examine colonic and small intestinal barrier function, we injected a reactive biotin tracer into the intestinal lumen of three week old *St14^−^* and littermate *St14*^+^ mice and followed the fate of the marker using fluorescent streptavidin. Compatible with an intact intestinal barrier function, the biotin marker decorated the surface of colonic crypts and villi of the small intestine, but did not penetrate into the tissue of *St14^+^* mice ([Figure 5a and d](#F5){ref-type="fig"}). In contrast, just three minutes after intraluminal biotin injection, the biotin tracer could be found on the basolateral membranes and on connective tissue cells of the colon and small intestine of *St14^−^* mice demonstrating a profound failure to establish a functional intestinal barrier ([Figure 5b and e](#F5){ref-type="fig"}).

Neoplastic progression occurs within a chronic inflammatory colonic microenvironment that resembles inflammatory bowel disease {#S6}
------------------------------------------------------------------------------------------------------------------------------

*St14*-ablated colonic tissue was histologically unremarkable when examined at birth and at postnatal day five (compare [Figures 6a and a′, b and b′](#F6){ref-type="fig"}). The first observable pathological manifestation (day 10) was the detachment and apoptosis (anoikis) of distal crypt cells (compare [Figure 6c and c′](#F6){ref-type="fig"}). This was followed by the failure of colonic epithelial cells to undergo proper terminal differentiation, as evidenced by cessation of mucin formation (data not shown). Thereafter, *St14*^−^ colons entered a progressively hyperplastic inflammatory and ulcerative state that eventually resulted in the gross distortion of colonic tissue architecture (compare [Figure 6d and d′, and 6e and e′](#F6){ref-type="fig"}). BrdU incorporating cells initially were confined to the bottom of the crypts, but later were present also in distal segments of the crypts (data not shown). Inflammatory infiltrates were evident at day 15. Inflammation at first was mild, but rapidly became severe, with inflammatory cells eventually constituting the dominant cell population of the mucosa and submucosa. Polyps were not observed in any of the examined colons prior to malignant transformation, indicating that *St14* ablation-associated adenocarcinomas, like inflammatory bowel disease-associated colorectal cancers arise from flat lesions within hyperproliferative and inflamed mucosa.

Abnormal epithelial differentiation and activation of inflammatory pathways precede inflammatory bowel disease-like colitis and dysregulation of common colon cancer-associated signaling pathways {#S7}
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

To elucidate the molecular events that precede the early development of colitis in mice with matriptase-ablated colonic epithelium, we next performed stage-specific transcriptomic analysis using whole-genome arrays. We selected two time points (days 0 and 5) where matriptase-ablated colonic epithelium was histologically normal, and one time point (day 10) where pathological changes were emerging (see above). The analysis was repeated four times for each of the three time points by analyzing individual *St14*^−^mice and their associated *St14*^+^ littermates. Genes that were more than two-fold up or downregulated in each of the four separate experiments were considered for analysis. No significant differences in the transcriptomes of *St14*-ablated and *St14*-sufficient colons were apparent at day 0 (data not shown). Interestingly, however, dysregulation of epithelial differentiation was apparent already at day 5 and was pronounced at day 10 ([Tables 2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}). This was evidenced by the conspicuous upregulation of genes typically expressed in basal, suprabasal or keratinizing layers of stratified squamous epithelium lining the oral cavity, interfollicular epidermis, hair and nails of follicular epidermis, and filiform papillae of the tongue. These included keratin 14 (*Krt14*), keratin 36 (*Krt36*), keratin 84 (*Krt84*), small protein-rich protein 1a (*Sprr1a*), small protein-rich protein 2h (*Sprr2h*), and secreted Ly6/Plaur domain containing 1 (*Slurp1*). Abnormal colonic epithelial differentiation at day five was further evidenced by the downregulation of the expression of Paneth cell-specific alpha-defensin 4 (*Defa4*). Although *St14^−^* colonic tissues were histologically normal at day 5, activation of inflammatory pathways was evidenced by the increased expression of several inflammation-associated genes, including chemokine (C-X-C motif) ligand-1 (*Cxcl1*), matrix metalloproteinase 10 (*Mmp10*), lymphocyte antigen 6 complex, locus C2 (*Ly6c2*), tumor necrosis factor (*Tnf*), myelin and lymphocyte protein (*Mal*), serum amyloid A3 (*Saa3*), lymphocyte antigen 6 complex, locus I (*Ly6i*), lymphocyte antigen 6 complex, locus D (*Ly6d*), and GPI-anchored molecule-like protein (*Gml*). Inflammatory circuit activation was manifest at day 10, with upregulated expression of a number of additional inflammation-associated genes, including receptor-interacting serine-threonin kinase 3 (*Ripk3*), lipopolysaccharide binding protein (*Lbp*), lactotransferrin (*Ltf*), TNFAIP3 interacting protein 3 (*Tnip3*), secretory leukocyte peptidase inhibitor (*Slpi*), leucine-rich alpha-2-glycoprotein 1 (*Lrg1*), and chemokine (C-X-C motif) ligand 5 (*Cxcl5*). Several epithelial proliferation-associated genes also were upregulated at day 10, including genes encoding the growth factors amphiregulin (*Areg*), heparin binding EGF-like growth factor (*Hbegf*), and the p53-binding proliferation inducer, tripartite-motif containing-29 (*Trim29*). Taken together, the combined stage-specific histological and transcriptomic analysis show that colonic epithelial ablation of matriptase causes aberrant early postnatal epithelial differentiation that triggers expression of pro-inflammatory mediators, which in turn causes persistent inflammation and chronic epithelial hyperproliferation.

Colonic tumor initiation in humans and animal models frequently is linked to dysregulated BMP, Notch, and Wnt signaling, leading to the expansion of the colonic stem cell population ([@R11], [@R20], [@R40], [@R74]). We therefore examined the level of expression of several putative and validated colonic stem cell markers (*Aldh1a1*, *Ascl2*, *Ets2*, *Lgr5*, *Phlda1*), as well as BMP (*Cbfb*, *Dlx2*, *Hes1*, *Id1*, *Id2*, *Id3*, *Id4*, *Junb*, *Sox4*, *Stat1*), Notch (*Cdkn1a*, *Ccdn1*, *Cdk2*, *Hes1*, *Hes6*, *Klf4*, *Myc*, *Nfkb2*), and Wnt (*Ascl2*, *Axin2*, *Cd44*, *Csnk1a1*, *Csnk1d*, *Csnk1e*, *Ctnnb1*, *Cryl1*, *Ephb2*, *Ephb3*, *Gfi1*, *Hdac2*, *Id3*, *Ihh*, *Lef1*, *Myc*, *Nkd1*, *Nlk*, *Pascin2*, *Pcna*, *Plat*, *Rbbp4*, *Snai1*, *Sox4*, *Sox9*, *Spdef*, *Stra6*, *Tcf4*, *Yes1*) target genes in *St14*^−^ mice and their associated *St14*^+^ littermates ([Supplementary Table 2](#SD5){ref-type="supplementary-material"}). This transcriptomic analysis provided no clear evidence of stem cell expansion or dysregulation of either of the three signaling pathways at day 0, at day 5, when abnormal differentiation and innate immune activation were apparent, or even at day 10, when abnormal colonic morphology was manifest. In agreement with this analysis, expression of the Wnt target, Sox9, in *St14*^−^ mice was appropriately confined to the crypts at day 10, and aberrant localization of Sox9 was not detected until day 15 ([Supplementary Figure 2](#SD2){ref-type="supplementary-material"}).

Diminution of the intestinal microbiota retards development of inflammatory bowel disease-like colitis {#S8}
------------------------------------------------------------------------------------------------------

We hypothesized that the chronic inflammatory microenvironment that facilitated neoplastic progression of *St14*-ablated colonic epithelium was generated in part by increased exposure of the mucosal immune system to the resident microbiota due to impaired barrier formation and aberrant differentiation. To challenge this hypothesis, we next treated weaning-age *St14*^−^ mice with a cocktail of the four antibiotics, ampicillin, neomycin, metronidazole, and vancomycin or with vehicle for two weeks, a standard procedure for cleansing of the intestinal microbiota ([@R50]). Due to the failure of some of the four antibiotics to be present in milk, the treatment was initiated at weaning, when significant pre-neoplastic progression was already apparent ([Figure 6e and e′](#F6){ref-type="fig"}). As expected, antibiotics treatment reduced the colonic bacterial load by approximately 1,500-fold, as judged by the abundance of bacterial 16S ribosomal DNA in feces ([Figure 7a](#F7){ref-type="fig"}), without compromising body weight ([Figure 7b](#F7){ref-type="fig"}). Helicobacter is found commonly in the commensal microbiota of mice and promotes neoplastic progression in a variety of models of colon carcinogenesis ([@R13], [@R14], [@R19], [@R37], [@R44]). We therefore specifically determined the presence of helicobacter DNA in feces of antibiotics-treated and untreated *St14*^−^ mice by PCR analysis ([Supplementary Table 3](#SD6){ref-type="supplementary-material"}). Nine of 17 (53%), 7/17 (41%), and 1/17 (6%) of control mice tested were positive for*Helicobacter typhlonius*, *Helicobacter rodentium*, and an undetermined *Helicobacter* species, respectively, whereas 2/13 (15%) of the analyzed antibiotics-treated mice were positive for *Helicobacter typhlonius*. Although initiated only after weaning, antibiotics treatment markedly blunted abnormal epithelial differentiation, epithelial hyperproliferation and inflammation of the colon. This was evidenced by a quantitative reduction in colonic mucosal thickness ([Figure 7c](#F7){ref-type="fig"}), increased mucin production ([Figure 7d](#F7){ref-type="fig"}, [Figure 8a and b](#F8){ref-type="fig"}), decreased epithelial proliferation ([Figure 7e](#F7){ref-type="fig"}, [Figure 8c and d](#F8){ref-type="fig"}), and decreased inflammatory cell infiltration ([Figure 7f--h](#F7){ref-type="fig"}, [Figure 8e--j](#F8){ref-type="fig"}), although the diminution of T-cell and neutrophil abundance did not reach statistical significance. Furthermore, β-catenin expression levels were normalized in two of four antibiotics-treated *St14^−^* mice when analyzed by immunoblot ([Supplementary Figure 3A](#SD3){ref-type="supplementary-material"}, compare lanes 7--10 with 13 and 14), and Sox9 was only infrequently found in the distal portion of the colonic crypts of antibiotics-treated *St14^−^* mice ([Supplementary Figure 2d and e](#SD2){ref-type="supplementary-material"}), suggesting a diminution of Wnt signaling. Analysis of BMP (phospho-SMAD1/5) and Notch1 (Notch1 intracellular domain) signaling did not reveal a treatment- or genotype-specific pattern, but the abundance of each of the two protein species in intestinal tissue extracts was difficult to assess accurately ([Supplementary Figure 3B](#SD3){ref-type="supplementary-material"}).

Taken together, the data are compatible with a principal role of the commensal microbiota in pre-neoplastic progression. A mechanistic model for matriptase ablation-induced colon cancer based on the above findings is shown in [Figure 9](#F9){ref-type="fig"}. We propose that the intrinsic defect in barrier function associated with the failure to form functional tight junctions ([@R8], [@R33]) causes increased exposure of the immune system to the commensal microbiota. This exposure elicits vigorous inflammatory and repair responses that involve epithelial stem cell activation and are continuous, rather than transient, due to the inherent failure of matriptase-ablated colonic epithelial cells to establish a functional barrier. The sustained hyperproliferation of epithelial stem cells within a genotoxic chronic inflammatory microenvironment in turn induces the progressive genomic instability and subsequent rapid malignant conversion.

Discussion {#S9}
==========

It has long been suspected that intrinsic alterations in the paracellular intestinal permeability barrier in humans could be a priming factor for the development of the aberrant immune response to the commensal microbiota that underlies inflammatory bowel disease and its associated malignancies. The current study now provides strong experimental support for this notion by showing that intestinal epithelial-specific ablation of matriptase - a membrane-anchored serine protease that is essential for intestinal epithelial tight junction formation - causes a commensal microbiota-dependent inflammatory bowel disease-like colitis that very rapidly progresses to adenocarcinoma. The spontaneous and rapid malignant transformation of the colonic epithelium furthermore demonstrates that a simple increase in intestinal paracellular permeability suffices to both initiate and drive inflammation-associated adenocarcinoma formation. This finding parallels the recent identification of the permeability of the epidermal barrier as a major determinant of the development of other chronic inflammatory diseases, including ichthyosis vulgaris, atopic eczema, and asthma ([@R57], [@R60]). Previously published animal models of inflammatory bowel disease-associated colorectal cancer include dextran sodium sulphate- or dextran sodium sulphate combined with azoxymethane-induced chemical colon carcinogenesis in inbred mouse strains ([@R46], [@R47]), and genetic models, including germline *Il10*- ([@R4]), combined germline *Tbx21*- and *Rag2*- ([@R17]), myeloid lineage *Stat3*- ([@R12]), myeloid lineage *Itgav*- ([@R28]), germline *Gnai2*- ([@R54]), and combined germline *Il2*- and *b2m*-ablated mice ([@R59]). In these models, colitis and colon carcinoma occur as a consequence of either a sustained chemical damage to the colonic epithelium or perturbation of the immune system through elimination of key effectors of innate or adaptive immunity. Compared to the above models, colon carcinogenesis in intestinal *St14*-ablated mice appears to display some unique features. First, it is initiated by a loss of intestinal barrier function, which is associated with aberrant differentiation and immune activation, but these priming events initially occur in the absence of detectable perturbation of common colon cancer-associated signaling pathways ([@R23]). Second, adenocarcinoma with involvement of lymphoid tissues is observed even in very young animals. This very rapid neoplastic progression may be explained, at least in part, by the presence of various helicobacter species in the intestinal microbiota of *St14^−^* mice, as colon carcinogenesis in several mouse models has been shown to be accelerated by or to be dependent upon helicobacter colonization ([@R13], [@R14], [@R19], [@R37], [@R44]).

In light of the findings in this study, it is tempting to speculate that neoplastic progression in previously described mouse models of inflammatory bowel disease-associated colorectal cancer (and perhaps colitis-associated human colorectal cancer) may be accelerated by an immune activation-induced decrease in the intestinal paracellular permeability barrier caused by downregulating the activity of matriptase or other molecules within a matriptase-dependent proteolytic pathway that facilitates tight junction formation.

Conclusive links have been forged between increased activity of multiple members of the complement of extracellular and pericellular proteases and the initiation and progression of a vide variety of human malignancies (reviewed in ([@R2], [@R6], [@R25], [@R41], [@R42])). Much less studied is the capacity of extracellular/pericellular proteases to act as suppressors of tumorigenesis (reviewed in ([@R34], [@R35])). Induced germline or lineage-specific gene deletion studies in mice as well as spontaneous somatic mutation analysis of human cancers have provided direct evidence for a tumor suppressive function of MMP3 ([@R38], [@R39]), MMP8 ([@R3], [@R49]), MMP12 ([@R1]), and Cathepsin L ([@R51]). Furthermore, the frequent epigenetic and genetic silencing of other extracellular and pericellular proteases in human cancers and the ability to inhibit distinct steps of tumor progression in experimental models of cancer through modulation of their level of expression suggest that the number of extracellular and pericellular proteases with tumor suppressive function may be substantial (reviewed in ([@R34], [@R35])). The current study adds matriptase to the above list of pericellular proteases with tumor suppressive functions. Matriptase, however, so far is unique among pericellular proteases in the sense that its absence by itself suffices to cause malignancy, whereas tumor suppressive function of other proteases was revealed in chemical and transplantation models of cancer.

Previous studies have shown that overexpression of matriptase can initiate carcinogenesis and accelerate the dissemination of a variety of carcinomas in diverse model systems. This property of matriptase is owed at least in part to its ability to autoactivate ([@R45]) and subsequently serve as an initiator of several intracellular signaling and proteolytic cascades through proteolytic maturation of growth factors, protease activated receptor activation, and protease zymogen conversion ([@R5], [@R9], [@R16], [@R21], [@R22], [@R26], [@R29], [@R32], [@R43], [@R48], [@R56], [@R64], [@R66], [@R68], [@R70]). The dual ability of a protease to promote carcinogenesis in some contexts, while suppressing carcinogenesis in others, is rare, but not entirely unprecedented. A clear example is given by the tumor promoting effect of transgenic misexpression of the stromal protease, MMP3, in the mammary epithelial compartment, as opposed to the strong protection of mice from chemically-induced squamous cell carcinogenesis caused by germ-line ablation of the protease ([@R38], [@R39], [@R61], [@R62]). Additional proteases, such as MMP9, MMP11, and MMP19 may also promote or suppress, respectively, malignant progression in a stage or tissue-dependent manner ([@R34]).

In conclusion, our study has uncovered a critical role of the transmembrane serine protease matriptase in preserving immune homeostasis in the gastrointestinal tract and suppressing the formation of colitis and colitis-associated adenocarcinoma formation. Furthermore, the study surprisingly reveals that the simple perturbation of the epithelial permeability barrier suffices to rapidly and efficiently induce malignant transformation of colonic epithelium.

Materials and Methods {#S10}
=====================

Animal experiments {#S11}
------------------

All procedures involving live animals were performed in an Association for Assessment and Accreditation of Laboratory Animals Care International-accredited vivarium following institutional guidelines and standard operating procedures. Within the study period, sentinels within the mouse holding room sporadically tested positive for helicobacter, murine norovirus, and mouse parvovirus, and tested negative for ectromelia virus, mouse rotavirus, Theiler's encephalomyelitis virus (GDVII strain), lymphocytic choriomeningitis virus, mycobacteria, mouse hepatitis virus, minute virus of mice, mouse polyoma virus, pneumonia virus of mice, reovirus type 3, Sendai virus, and fecal endo and ectoparasites. The NIDCR Institutional Animal Care and Use Committee approved the study. All studies were strictly littermate controlled. *St14* knock out (*St14^−/−^*) and conditional knockout (*St14^LoxP/LoxP^*) mice have been described previously ([@R31], [@R33]). *Villin-Cre^+/0^* \[B6.SJL-Tg(Vil-Cre)997Gum/J\] mice ([@R36]) were purchased from The Jackson Laboratory (Bar Harbor, ME). All experimental animals were in a mixed 129/C57BL6/J/NIH Black Swiss/FVB/NJ background. The genotypes of all mice were determined by PCR of ear or tail biopsy DNA. *St14*^+^ and *St14^LoxP^* alleles were detected using the primers 5′-CAGTGCTGTTCAGCTTCCTCTT-3′ and 5′-GTGGAGGTGGAGTTCTCATACG-5′. The presence of the *St14* knock out allele was detected using primers 5′-GTGGAGGTGGAGTTCTCATACG-3′ and 5′-GTGCGAGGCCAGAGGCCACTTGTGTAGCG-3′. The Cre transgene was detected using the primers 5′-GCATAACCAGTGAAACAGCATTGCTG-3 ′ and 5 ′-GGACATGTTCAGGGATCGCCAGGCG-3′. For antibiotics treatment, mice were given a combination of ampicillin (1 g/l, Sigma-Aldrich, St. Louis, MO), neomycin (1 g/l, Sigma-Aldrich), metronidazole (1 g/l, Sigma-Aldrich), and vancomycin (0.5 g/l, Sigma-Aldrich) in the drinking water for two weeks, starting immediately after weaning (P20).

Quantitative PCR analysis {#S12}
-------------------------

RNA was prepared from mouse organs by extraction in TRIzol reagent (Invitrogen, Carlsbad, CA), as recommended by the manufacturer. First strand cDNA synthesis was performed using oligo (dT) primers with the iScript^™^ cDNA synthesis kit (Bio-Rad Laboratories, Hercules, CA). An iCycler, gene expression analysis software, and IQ SYBR Green Supermix (all from Bio-Rad Laboratories) were used for quantitative PCR analysis in accordance with the manufacturer's instructions, using a primer complementary to sequence of matriptase exon 1, 5′-AACCATGGGTAGCAATCGGGGC-3′, and matriptase exon 2, 5′-AACTCCACACCCTCCTCAAAGC-3′ (annealing temperature 60 °C, denaturation temperature 95 °C, 40 cycles). Matriptase expression levels were normalized to glyceraldehyde-3-phosphate dehydrogenase (*Gapdh*) levels in each sample. *Gapdh* mRNA was amplified with the primers 5′-GTGAAGCAGGCATCTGAGG-3′ and 5′-CATCGAAGGTGGAAGAGTGG-3′ (annealing temperature 60 °C, denaturation temperature 95 °C, 40 cycles).

Quantification of bacterial intestinal colonization {#S13}
---------------------------------------------------

Bacterial DNA was isolated from feces using QIAamp DNA Stool Mini Kit (Qiagen, Valencia, CA) according to manufacturer's instructions. Bacterial DNA was quantified by qPCR analysis of bacterial 16S ribosomal DNA, amplified by primers: 8FM (5′-AGAGTTTGATCMTGGCTCAG-3′) and Bact 5 15 R(5′-TTACCGCGGCKGCTGGCAC-3′). An iCycler, gene expression analysis software, and IQ SYBR Green Supermix were used for real-time PCR in accordance with the manufacturer's instructions. The thermal cycling program consisted of 95 °C for 10 min, followed by 40 cycles of 95 °C for 30 s, 55 °C for 30 s, 60 °C for 45 s, 65 °C for 15 s and 72 °C for 15 s. Helicobacter testing was performed as described previously ([@R15], [@R53]).

Intestinal tight junction assay {#S14}
-------------------------------

Fifty ul of 10 mg/ml EZ-Link Sulfo-NHSLC-Biotin (Thermo Fisher Scientific, Waltham, MA) in PBS containing 1 mmol/L CaCl~2~ was injected into the lumen of distal colon and jejunum of three week old *St14^−^* and *St14^+^* littermates that were anesthetized by intraperitoneal injection of an anesthetic combination (ketamine \[20 mg/ml\], xylazine \[2 mg/ml\], 50 ul/10 g). After 3 min incubation, the mice were euthanized, and the injected portion of the intestine was excised and fixed in 10% neutral-buffered zinc formalin (Z-fix, Anatech, Battle Creek, MI) for 3 h, processed into paraffin and sectioned. Five μm sections were blocked for 30 min in blocking solution (5% bovine serum albumin in PBS), and then incubated for 1 h at room temperature with streptavidin Alexa Fluor 448 conjugate (Invitrogen) (5 ug/ml) in blocking solution. Sections were washed three times with PBS and mounted with VECTASHIELD HardSet Mounting Medium with DAPI (Vector Laboratories, Burlingame, CA). Images were acquired on an Axio Imager. Z1 microscope using an AxioCam HRc/MRm digital camera (Carl Zeiss Ldt, Jena, Germany).

Histopathology {#S15}
--------------

Mice were euthanized by CO~2~ inhalation. Tissues were fixed for 24 h in Z-fix, processed into paraffin, cut into 5 μm sections, and stained with hematoxylin and eosin (H&E). For visualization of mucin production, sections were stained with the Periodic Acid-Schiff (PAS) kit (Sigma-Aldrich) or Alcian Blue (1% Alcian Blue in 3% acetic acid). Collagen was detected using Masson-trichrome staining.

Immunohistochemistry {#S16}
--------------------

Tissue sections were prepared and antigens were retrieved by heating in epitope retrieval buffer (0.01 M sodium citrate, pH 6.5) or Epitop Retrieval Buffer-Reduced pH (Bethyl Laboratories, Montgomery, TX) for matriptase IHC. The sections were blocked for 1 h in 5% bovine serum albumin (Sigma-Aldrich), or 10% horse serum (for matriptase IHC) in PBS, and incubated overnight at 4 C with primary antibody: matriptase (Sheep, Polyclonal, R&D Systems, Minneapolis, MN), cytokeratins (Rabbit, Polyclonal, DakoCytomation, Carpinteria, CA), LYVE-1 (Goat, Polyclonal, R&D Systems), β-catenin (Rabbit, Monoclonal, Cell Signaling, Danvers, MA), laminin (Rabbit, Polyclonal, Sigma-Aldrich), BrdU (Rat, Monoclonal, Accurate Chemicals & Scientific, Westbury, NY), CD3 (Rabbit, Polyclonal, DakoCytomation), κ-light chain (Rabbit, Polyclonal, DakoCytomation), Ki67 (Rabbit, Polyclonal, Novocastra, Westbury, NY), myeloperoxidase (Rabbit, Polyclonal, DakoCytomation), and Sox9 (Rabbit, Polyclonal, Millipore, Temecula, CA). Bound antibodies were visualized using either biotin-conjugated horse anti-goat, goat anti-rabbit, goat anti-rat (Vector Laboratories, Burlingame, CA), rabbit anti-sheep (Thermo Scientific, Rockford, IL), or alkaline phosphatase-conjugated donkey anti-rabbit (DakoCytomation) secondary antibodies and a VECTASTAIN ABC kit (Vector Laboratories) using 3,3′-diaminobenzidine substrate (Sigma-Aldrich) or Vulcan Fast Red Chromogen Kit 2 (Biocare Medical, Concord, CA). Hematoxylin was the counterstain.

Immunoblotting {#S17}
--------------

Approximately 1 cm of the distal part of large intestine was homogenized and lysed in 25 mM Tris-HCl, pH 7.6, 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS and protease inhibitor cocktail (Sigma). Boiled and reduced samples were subjected to immunoblotting using primary antibodies: anti-β-catenin (Rabbit, Monoclonal, Cell Signaling), anti-phospho-SMAD1/5 (Rabbit, monoclonal, Cell Signaling), anti-Notch1 (Rabbit, monoclonal, Cell Signaling), and anti-GAPDH (Rabbit, polyclonal, Santa Cruz, Santa Cruz, CA). The signal was detected with secondary anti-rabbit antibody conjugated to either alkaline phosphatase (Dako) or horseradish peroxidase (Thermo Scientific).

Microarray analysis {#S18}
-------------------

Microarray analysis of gene expression was performed using Mouse GE 4×44K v2 Microarray slides (Agilent Technologies, Santa Clara, CA) according to manufacturer's instructions. Briefly, colon tissue was dissected from four pairs of *St14^−^* and littermate *St14^+^* mice. RNA was isolated using TRIzol reagent, as recommended by the manufacturer. The quality and the integrity of the RNA was determined by the 2100 Bioanalyzer platform (Agilent Technologies). Isolated colon RNA together with Universal Mouse Reference RNA (Agilent Technologies) was labeled using the Two-color Quick Amp Labeling Kit (Agilent Technologies). Labeled RNA was hybridized to the slides overnight. After washing the slides were scanned using a High Resolution Microarray Scanner. The raw microarray image files were read and processed with Feature Extraction Software. The analysis of microarray data was performed using Gene Spring Software (all from Agilent Technologies). Gene expression was normalized to the universal reference RNA. From the original data set, only probes flagged as detected at least in one sample were selected. These data sets were further filtered for probes with 2-or more fold change in expression between *St14^+^* and *St14^−^* tissue. Statistical analysis of these data sets led to the identification of probes with significantly different change in gene expression using unpaired Student's t-test with Benjamini-Hochberg multiple testing correction. Probes with P \< 0.05 were considered significant and are shown in [Tables 2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}.

Histomorphometric analysis {#S19}
--------------------------

Five control *St14^−^* and six antibiotics treated *St14^−^* mice were analyzed. To determine the mucosal thickness, 2 mm of the distal colon mucosa adjacent to squamous epithelium of the rectum was identified on a H&E section and the area was calculated using Aperio ImageScope software (Aperio, Vista, CA). For the quantification of proliferation, differentiation and inflammatory infiltrates, seven individual areas of distal colon on each slide were selected for counting. The number of counts was normalized to the surface of the selected area and averaged for each individual animal.

Supplementary Material {#S20}
======================

###### Supplementary Figure 1. Tissue-specific ablation of matriptase from the gastrointestinal tract causes growth retardation and diminished life span

(a--d) Representative examples of matriptase immunohistochemical analysis of epithelium of large (a,b) and small (c,d) intestine of three week old *St14^+^* (a,c) and *St14^−^* (b,d) mice showing loss of matriptase (examples with arrows) from basolateral membranes of intestinal epithelial cells. Scale bar = 50 μm. (e) Quantitative PCR analysis of *St14* mRNA levels in colon (left panel), small intestine (middle panel), and kidney (right panel) of four weaning age *St14^+^* (left bars) and four littermate *St14^−^* (right bars) mice showing efficient Cre-mediated ablation of *St14* mRNA in intestinal tissues. mRNA levels are normalized to *Gapdh* and are shown as mean ± SEM. Statistical significance was calculated by Student's t-test (two-tailed), N.S. = not significant. (f) Representative example of the external appearance of *St14^−^* (left) and littermate *St14^+^* control mouse (right) at four weeks of age showing decreased body size. (g) Kaplan-Meier analysis of survival of *St14^+^* (N=26) and littermate *St14^−^* (N=20) mice followed for up to 80 days. Statistical significance was determined by the log-rank test, two-tailed.

###### Supplementary Figure 2. Matriptase ablation in large intestine leads to spatial dysregulation of Wnt target -- Sox9

Immunohistochemical staining for Sox9 in *St14^+^* (**a**,**b**,**c**) and *St14^−^* (**a**′,**b**′,**c**′,**d**,**e**) colons at postnatal day 10 (**a**,**a**′), 15 (**b**,**b**′) and 20 (**c**,**c**′) shows appropriate localization of Sox9 in the crypts of control *St14^+^* animals (examples with **arrows** in **a**,**b**,**c**) and a very similar signal localization in *St14^−^* animals at postnatal day 10 (example with **arrow** in **a**′). Sox9 expression becomes dysregulated at postnatal days 15 and 20, as shown by Sox9-positive cells on the top of mucosa (examples with **arrowheads** in **b**′). Antibiotics treatment of *St14^−^* mice (**e**) reduces aberrant Sox9 expression (compare examples with **arrownheads** in **d** and **e**). Scale bar = 50 μm.

###### Supplementary Figure 3. Assessment of Wnt, BMP and Notch signaling in antibiotics-treated *St14^−^* mice

Immunoblot analysis of large intestine tissue lysates of *St14*^−^ (lanes **4--5**, **11--14** in **A**, lanes **3--4**, **10--13** in **B**) and littermate control *St14^+^* animals (lanes **1--3**, **7--10** in **A**, lanes **1--2**, **6--9** in **B**) kept on regular water (lanes **1--6** in **A**, lanes **1--5** in **B**) or on antibiotics treatment (lanes **7--14** in **A**, lanes **6--13** in **B**). (**A**) β-catenin expression pattern shows increased signal in all non-treated *St14^−^* animals (lanes **4--6**) and normal expression in two antibiotics treated *St14^−^* animals (lanes **13--14** in **A**). (**B**) Immunoblot analysis of phospho-SMAD1/5 and intracellular (NID) Notch1 domain does not reveal a treatment- or genotype- specific expression pattern. Immunoblot analysis of Gapdh expression was used as a protein loading control. Positions of molecular weight markers (kD) are shown on the right.
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![Matriptase expression is downregulated in human colon adenomas and adenocarcinomas\
Expression of *ST14*, encoding matriptase, in 14 gene expression array studies of human colon adenomas and adenocarcinomas. Data are expressed as fold change relative to corresponding normal tissue. \**P\<*0.05, \*\**P*\<0.01, \*\*\**P*\<0.001. See [Supplementary Table 1](#SD4){ref-type="supplementary-material"} for details and references.](nihms334975f1){#F1}

![Rapid and spontaneous malignant transformation of *St14*-ablated colonic epithelium\
(**a**) Representative example of adenocarcinoma in the large intestine of an eight week old *St14^−^* mouse. Tumor cells invading the muscularis externa (**star**) are shown with **arrows**. (**b**) The epithelial origin of the tumor cells invading the muscularis externa (**star**) is demonstrated by immunohistochemical staining for keratin (examples with **arrows**). (**c**) Combined immunohistochemical staining for keratin in red (examples with **arrows**) and the lymphatic vessel marker LYVE-1 in brown (examples with **arrowheads**) shows invasion of malignant cells into lymphatic vessels of a seven week old *St14^−^* mouse. Scale bar for **a**, **b**, and **c** = 100 μm. (**d**) Enumeration of colonic lesions in four to 18 week old *St14^+^* (left) and littermate *St14^−^* mice (right), showing adenocarcinoma with lymphatic invasion in 6, adenocarcinoma without lymphatic invasion in 2, and regenerative atypia in the remaining 16 *St14^−^* mice. See [Table 1](#T1){ref-type="table"} for additional details.](nihms334975f2){#F2}

![Characterization of matriptase ablation-associated colon adenocarcinoma\
(**a**,**a**′) Immunohistochemical staining of eight week old *St14^+^* (**a**) and littermate *St14^−^* (**a**′) colons for β-catenin shows a membrane-associated β-catenin localization in *St14^+^* epithelial cells (**arrows** in **a**), as compared to cytoplasmic and nuclear localization in adenocarcinomas of *St14^−^* colons (examples with **arrows** in **a**′). (**b**,**b**′) Immunohistochemical staining for the basement membrane marker laminin in 15 week old *St14^+^* (**b**) and littermate *St14^−^* (**b**′) mice shows the normal appearance of the basement membrane (example with **arrow** in **b**) in *St14^+^* mice. Loss of matriptase expression leads to increased deposition of laminin (examples with **stars** in **b**′) and loss of normal structure of the basement membrane. (**c**,**c**′) Masson Trichrome staining of the colon of six week old *St14^+^* (**c**) and littermate *St14^−^* (**c**′) mice shows connective tissue in the submucosa of a normal colon (example with **arrow** in **c**) and fibrosis of both the mucosa and submucosa of *St14^−^* colon (examples with **stars** in **c**′). (**d**) High magnification shows the cytological appearance of adenocarcinomas of *St14^−^* mice. Atypical mitosis is shown by **arrows**. Scale bar = 200 μm (**a**, **a**′,**b**,**b**′,**c**,**c**′) and 20 μm (**d**).](nihms334975f3){#F3}

![Characterization of matriptase ablation-associated colon adenocarcinoma\
(**a**,**a**′) BrdU staining of eight week old *St14^+^* (**a**) and littermate *St14^−^* (**a**′) mice shows proliferation restricted to the bottom of the crypts of normal colons (examples with **arrows** in **a**). In *St14^−^* colon, proliferating cells are found both in the bottom (examples with **arrows** in **a**′) and distal parts of crypts (examples with **arrowheads** in **a**′). **(b,b**′**)** Periodic Acid-Schiff (PAS) staining of mucopolysaccharides produced by differentiated goblet cells in the colon of eleven week old *St14^+^* (**b**) and littermate *St14^−^* (**b**′) mice. Red staining shows mucin in the normal colon (**arrows** in **b**). Absence of red staining in (**b**′) indicates cessation of mucin production in matriptase-ablated colon. (**c**,**c**′,**d**,**d**′) Immunohistochemical staining for T-cells (**c**,**c**′) and B-cells (**d**,**d**′) in, respectively, seven and 15 week old *St14^+^* (**c**, **d**) and littermate *St14^−^* (**c**′,**d**′) colons. Baseline levels of T-and B-cells in the lamina propria of *St14^+^* colon (examples with **arrows** in **d** and **c**) and abundance of T- and B-cells in both mucosa and submucosa of *St14^−^* colons (examples with **stars** in **c**′,**d**′). Scale bar = 100 μm.](nihms334975f4){#F4}

![Matriptase-ablated colon is leaky\
The lumen of the colon and small intestine of weaning age *St14^+^* and littermate *St14^−^*animals was injected with Sulfo-NHS-LC-Biotin in PBS (**a**,**b**,**d**,**e**) or PBS (**c**,**f**). After three min, the intestine was excised, sectioned, and stained for biotin (**green**). Nuclei were stained with 4,6-diamino-2-phenylindol (**blue**). **Arrows** in **a**, **d**, and **e** show biotin bound to the surface of the mucosa. **Arrowheads** in **b** and the **inset** in **e** show biotin labeling of the basolateral membrane of polarized epithelial cells. The diffusion of biotin into intercellular space was not observed in the normal colon or small intestine (**a**,**d**, also compare **insets** in **d** and **e**). Stars show biotin labeling of connective tissue of both matriptase-ablated colon (**b**) and small intestine (**e**). There was no signal for biotin in colon and small intestine (**c**,**f**) injected with PBS. Scale bar = 20 μm.](nihms334975f5){#F5}

![Progressive postnatal loss of epithelial integrity of matriptase-ablated colon precedes malignant transformation\
Histological appearance of *St14^+^* (**a**--**e**) and littermate *St14^−^* (**a**′-**e**′) colons at postnatal day 0 (**a**,**a**′), 5 (**b**,**b**′), 10 (**c**,**c**′), 15 (**d**,**d**′), and 20 (**e**,**e**′). No histological differences can be observed between normal and matriptase-ablated colon at days 0 and 5 (compare **a** and **a**′, **b** and **b**′). At day 10, *St14^−^* colons show sporadic foci of detaching and apoptotic cells (**arrowheads** in **c**′). This phenotype is significantly stronger at days 15 and 20 with extensive anoikis (**arrowheads** in **d**′), apoptotic cells (**arrows** in **d**′, **e**′), ulcerations (**arrowhead** in **e**′) and inflammatory cell infiltrates (**star** in **e**′). Scale bar = 100 μm.](nihms334975f6){#F6}

![The resident microbiota contributes to preneoplastic progression of matriptase-ablated colon\
Littermate *St14^−^* mice were kept on regular water (**control** in **a**--**h**) or treated with a combination of ampicillin, neomycin, metronidazole, and vancomycin in the drinking water (**antibiotics** in **a**--**h**) for two weeks starting immediately after weaning. The animals were euthanized, the feces was used for the isolation of bacterial DNA, and the colonic tissue was subjected to quantitative histomorphometric analysis. (**a**) PCR quantification of 16S bacterial ribosomal DNA shows a 1 500-fold decrease in the intestinal microbiota of antibiotics treated (N=15) compared to control (N=13) mice. (**b**) Body weight of antibiotics treated (N=7) and control (N=7) is similar. (**c**) Decreased thickness of the mucosa of antibiotics treated (N=6) compared to control (N=5) mice. (**d**--**f**) Preservation of mucin production (**d**), decreased proliferation (**e**), and decreased infiltration of B-cells (**f**), T-cells (**g**) and neutrophils (**h**) in antibiotics treated (N=6) compared to (N=5) mice. Statistical significance was calculated by Student's t-test (two-tailed) (**a**--**c**, **e**--**h**), and non-parametric Mann-Whitney U-test (two-tailed) (**d**), N.S. = not significant.](nihms334975f7){#F7}

![Histological appearance of antibiotics treated matriptase-ablated colon\
(**a**,**b**) Alcian Blue staining of mucin produced by differentiated goblet cells in untreated (**a**) and antibiotics treated (**b**) *St14^−^* colons. **Arrowheads** point to mucin (**blue**). (**c**,**d**) Immunohistochemical staining for Ki67 in untreated (**c**) and antibiotics treated (**d**) *St14^−^*mice show significantly decreased rates of proliferation of both epithelial cells (**arrowheads** in **c**,**d**) and connective tissue cells (**arrows** in **c**,**d**). (**e**--**j**) Immunohistochemical staining for B-cells (**e**,**f**), T-cells (**g**,**h**), and neutrophils (**i**,**j**) in untreated (**e**,**g**,**i**) and antibiotics treated (**f**,**h**,**j**) *St14^−^* colons shows reduced chronic (examples with **arrowheads** in **e**--**h**) and acute (examples with **arrowheads** in **i** and **j**) inflammatory cell infiltration. Scale bar = 50 μm.](nihms334975f8){#F8}

![Model for matriptase ablation-induced colon carcinogenesis\
Loss of matriptase from intestinal epithelium compromises epithelial barrier function thereby causing exposure of the commensal microbiota to resident immune cells. This triggers a repair response that includes activation of local inflammatory circuits and colonic stem cell activation. This response is perpetual, rather than transient, due to the intrinsic inability of matriptase-ablated to form a functional barrier. Persistent hyperproliferation of colonic stem cells within a DNA damaging chronic inflammatory microenvironment causes the formation of adenocarcinoma.](nihms334975f9){#F9}

###### 

Intestinal lesions in *St14^−^* mice

  Mouse     Gender   Age (days)   Diagnosis of intestinal lesions   Lymphatic invasion
  --------- -------- ------------ --------------------------------- --------------------
  MCV41     Male     31           Regenerative atypia               No
  MCV52     Male     33           Adenocarcinoma                    Yes
  MCV55     Female   55           Regenerative atypia               No
  MCV56     Female   55           Regenerative atypia               No
  MCV59     Male     25           Regenerative atypia               No
  MCV66     Male     28           Regenerative atypia               No
  MCV70     Female   24           Regenerative atypia               No
  MCV76     Male     129          Regenerative atypia               No
  MCV127    Male     111          Regenerative atypia               No
  MCV153    Male     79           Adenocarcinoma                    No
  MCV159    Female   26           Regenerative atypia               No
  MCV162    Male     105          Adenocarcinoma                    Yes
  MCV173    Male     44           Regenerative atypia               No
  MCV180    Female   131          Adenocarcinoma                    No
  MCV192    Male     44           Regenerative atypia               No
  MCV204    Male     48           Adenocarcinoma                    Yes
  MCV234    Male     50           Adenocarcinoma                    Yes
  MCV256    Male     56           Adenocarcinoma                    Yes
  MCV359    Female   51           Adenocarcinoma                    Yes
  MCV366    Male     36           Regenerative atypia               No
  MCV397    Male     39           Regenerative atypia               No
  MCV461    Female   30           Regenerative atypia               No
  MCV468    Male     22           Regenerative atypia               No
  MCV1250   Male     67           Regenerative atypia               No

###### 

Genes differently regulated in 5 days old *St14^−^* mice

  Agilent Probe ID   GenBank        Regulation   Fold change[1](#TFN1){ref-type="table-fn"}   P-value[2](#TFN2){ref-type="table-fn"}   Gene symbol   Gene Name
  ------------------ -------------- ------------ -------------------------------------------- ---------------------------------------- ------------- ---------------------------------------------------------------------------------
  A_51_P124665       NM_011474      up           17.86                                        *0.001*                                  *Sprr2h*      small proline-rich protein 2H
  A_51_P272066       NM_025929      up           9.40                                         *0.001*                                                RIKEN cDNA 2010109I03 gene
  A_51_P451966       NM_001177524   up           5.39                                         *0.035*                                  *Gml*         GPI anchored molecule like protein
  A_52_P151240       NM_001195732   up           4.34                                         *0.024*                                  *Fam150a*     predicted gene, family with sequence similarity 150, member A
  A_51_P343517       NM_010742      up           3.87                                         *0.027*                                  *Ly6d*        lymphocyte antigen 6 complex, locus D
  A_51_P363187       NM_008176      up           3.13                                         *0.001*                                  *Cxcl1*       chemokine (C-X-C motif) ligand 1
  A_51_P291950       NM_010266      up           2.91                                         *0.037*                                  *Gda*         guanine deaminase
  A_52_P545650       NM_001174099   up           2.83                                         *0.011*                                  *Krt36*       keratin 36
  A_51_P187121       NM_008127      up           2.63                                         *0.028*                                  *Gjb4*        gap junction protein, beta 4
  A_51_P411495       XM_897643      up           2.50                                         *0.045*                                                RIKEN cDNA 4930465A12 gene
  A_51_P420918       NM_020498      up           2.39                                         *0.050*                                  *Ly6i*        lymphocyte antigen 6 complex, locus I
  A_51_P367880       NM_008474      up           2.35                                         *0.037*                                  *Krt84*       keratin 84
  A_51_P120830       NM_019471      up           2.29                                         *0.037*                                  *Mmp10*       matrix metallopeptidase 10
  A_51_P385639       NM_010291      up           2.28                                         *0.011*                                  *Gjb5*        gap junction protein, beta 5
  A_51_P337308       NM_011315      up           2.27                                         *0.019*                                  *Saa3*        serum amyloid A 3
  A_51_P228574       NM_146214      up           2.26                                         *0.043*                                  *Tat*         tyrosineaminotransferase
  A_52_P562661       NM_010762      up           2.17                                         *0.023*                                  *Mal*         myelin and lymphocyte protein, T-cell differentiation protein
  A_51_P499071       NM_010762      up           2.14                                         *0.011*                                  *Mal*         myelin and lymphocyte protein, T-cell differentiation protein
  A_51_P503494       NM_018790      up           2.11                                         *0.003*                                  *Arc*         activity regulated cytoskeletal-associated protein
  A_52_P299446       U90654         up           2.09                                         *0.013*                                                zinc-finger domain-containing protein
  A_52_P220241       AK164337       up           2.09                                         *0.032*                                                RIKEN cDNA A430106P18 gene, hypothetical proline-rich region containing protein
  A_51_P139678       NM_009264      up           2.09                                         *0.021*                                  *Sprr1a*      small proline-rich protein 1A
  A_51_P214275       NM_001174099   up           2.08                                         *0.023*                                  *Krt36*       keratin 36
  A_51_P245090       NM_016689      up           2.07                                         *0.020*                                  *Aqp3*        aquaporin 3
  A_51_P385099       NM_013693      up           2.06                                         *0.019*                                  *Tnf*         tumor necrosis factor
  A_52_P26416        AF106279       up           2.05                                         *0.045*                                  *Lamc2*       laminin gamma2 chain
  A_52_P445360       NM_023256      up           2.04                                         *0.028*                                  *Krt20*       keratin 20
  A_51_P197528       NM_001099217   up           2.03                                         *0.050*                                  *Ly6c2*       lymphocyte antigen 6 complex, locus C2
  A_52_P421234       NM_133832      up           2.02                                         *0.011*                                  *Rdh10*       retinol dehydrogenase 10
  A_51_P323195       NM_172613      down         4.65                                         *0.045*                                  *Atp13a4*     ATPase type 13A4
  A_52_P453814       NM_011242      down         3.09                                         *0.045*                                  *Rasgrp2*     RAS, guanyl releasing protein 2
  A_51_P394847       NR_024599      down         2.86                                         *0.045*                                                predicted gene 11346
  A_51_P492940       AK035376       down         2.63                                         *0.045*                                                RIKEN full-length enriched library, clone:9530027C22, unclassifiable product
  A_51_P394172       NM_007954      down         2.44                                         *0.021*                                  *Es1*         esterase 1
  A_51_P375969       NM_053200      down         2.37                                         *0.036*                                  *Ces3*        carboxylesterase 3
  A_52_P994399       NM_010039      down         2.34                                         *0.048*                                  *Defa4*       defensin, alpha, 4
  A_52_P115950       AK036853       down         2.28                                         *0.045*                                                RIKEN full-length enriched library, clone:9930018I23, hypothetical protein
  A_51_P391934       NM_029706      down         2.17                                         *0.050*                                  *Cpb1*        carboxypeptidase B1
  A_51_P358037       NM_001014423   down         2.06                                         *0.045*                                  *Abi3bp*      ABI gene family, member 3 (NESH) binding protein
  A_52_P819243       AK049777       down         2.05                                         *0.045*                                                RIKEN full-length enriched library, clone:C530048O03, hypothetical protein
  A_51_P242967       NM_021308      down         2.01                                         *0.011*                                  *Piwil2*      piwi-like homolog 2

Compared to expression in normal mucosa

Student's t-test (two-tailed, unpaired, asymptotic), Benjamini-Hochberg multiple testing correction

###### 

Genes differently regulated in 10 days old *St14^−^* mice

  Agilent Probe ID   GenBank                                             Regulation   **Fold change**[1](#TFN3){ref-type="table-fn"}   *P-value*[2](#TFN4){ref-type="table-fn"}   ***Gene symbol***   Gene Name
  ------------------ --------------------------------------------------- ------------ ------------------------------------------------ ------------------------------------------ ------------------- --------------------------------------------------------------------------------
  A_52_P295432       NM_009141                                           up           **32.09**                                        *0.044*                                    ***Cxcl5***         chemokine (C-X-C motif) ligand 5
  A_51_P124665       NM_011474                                           up           **28.95**                                        *0.037*                                    ***Sprr2h***        small proline-rich protein 2H
  A_51_P256827       NM_013650                                           up           **9.86**                                         *0.044*                                    ***S100a8***        S100 calcium binding protein A8 (calgranulin A)
  A_51_P346938       NM_029796                                           up           **8.30**                                         *0.044*                                    ***Lrg1***          leucine-rich alpha-2-glycoprotein 1
  A_51_P363187       NM_008176                                           up           **5.02**                                         *0.044*                                    ***Cxcl1***         chemokine (C-X-C motif) ligand 1
  A_52_P487686       NM_001082546                                        up           **4.36**                                         *0.044*                                                        cDNA sequence BC100530
  A_51_P279437       NM_029662                                           up           **3.98**                                         *0.048*                                    ***Mfsd2a***        major facilitator superfamily domain containing 2A
  A_51_P359046       NM_020519                                           up           **3.78**                                         *0.044*                                    ***Slurp1***        secreted Ly6/Plaur domain containing 1
  A_51_P303160       NM_007482                                           up           **3.71**                                         *0.044*                                    ***Arg1***          arginase
  A_51_P451966       NM_001177524                                        up           **3.58**                                         *0.044*                                    ***Gml***           GPI anchored molecule like protein
  A_52_P1172382      Q8C9Z4[3](#TFN5){ref-type="table-fn"}               up           **3.44**                                         *0.049*                                                        putative uncharacterized protein
  A_52_P472324       NM_011414                                           up           **3.13**                                         *0.044*                                    ***Slpi***          leukocyte peptidase inhibitor
  A_51_P200544       NM_001001495                                        up           **3.12**                                         *0.044*                                    ***Tnip3***         TNFAIP3 interacting protein 3
  A_51_P214275       NM_001174099                                        up           **3.10**                                         *0.037*                                    ***Krt36***         keratin 36
  A_51_P187461       NM_009044                                           up           **3.03**                                         *0.044*                                    ***Rel***           reticuloendotheliosis oncogene
  A_51_P116609       NM_025687                                           up           **2.87**                                         *0.044*                                    ***Tex12***         testis expressed gene 12
  A_52_P531140       NM_010416                                           up           **2.81**                                         *0.044*                                    ***Hemt1***         hematopoietic cell transcript 1
  A_52_P545650       NM_001174099                                        up           **2.74**                                         *0.038*                                    ***Krt36***         keratin 36
  A_52_P31510        NM_008814                                           up           **2.65**                                         *0.037*                                    ***Pdx1***          pancreatic andduodenal homeobox 1
  A_52_P273394       AK137552                                            up           **2.58**                                         *0.013*                                    ***Igl-5***         Immunoglobulin lambda chain 5
  A_51_P272066       NM_025929                                           up           **2.57**                                         *0.044*                                                        RIKEN cDNA 2010109I03 gene
  A_52_P116006       NM_010266                                           up           **2.57**                                         *0.044*                                    ***Gda***           guanine deaminase
  A_51_P225634       NM_027306                                           up           **2.50**                                         *0.044*                                    ***Zdhhc25***       zinc finger, DHHC domain containing 25
  A_52_P200286       NM_001167746                                        up           **2.46**                                         *0.044*                                    ***Dnahc17***       dynein, axonemal, heavy chain 17
  A_52_P482897       NM_009704                                           up           **2.40**                                         *0.044*                                    ***Areg***          amphiregulin
  A_52_P15388        NM_008522                                           up           **2.33**                                         *0.044*                                    ***Ltf***           lactotransferrin
  A_51_P500082       NM_001110517                                        up           **2.27**                                         *0.044*                                                        predicted gene 14446
  A_52_P884135       AK085881                                            up           **2.26**                                         *0.049*                                                        RIKEN full-length enriched library, clone:D830023G23, unclassifiable product
  A_51_P165182       NM_028967                                           up           **2.25**                                         *0.044*                                    ***Batf2***         basic leucine zipper transcription factor, ATF-like 2
  A_52_P338066       NM_023137                                           up           **2.24**                                         *0.049*                                    ***Ubd***           ubiquitin D
  A_51_P454008       NM_008489                                           up           **2.23**                                         *0.037*                                    ***Lbp***           lipopolysaccharide binding protein
  A_51_P291950       NM_010266                                           up           **2.22**                                         *0.044*                                    ***Gda***           guanine deaminase
  A_52_P375047       NM_009184                                           up           **2.22**                                         *0.039*                                    ***Ptk6***          PTK6 protein tyrosine kinase 6
  A_51_P409349       NM_023655                                           up           **2.21**                                         *0.046*                                    ***Trim29***        tripartite motif-containing 29
  A_51_P228971       NM_023219                                           up           **2.19**                                         *0.044*                                    ***Slc5a4b***       solute carrier family 5 (neutral amino acid transporters, system A), member 4b
  A_51_P249989       NM_145133                                           up           **2.19**                                         *0.047*                                    ***Tifa***          TRAF-interacting protein with forkhead-associated domain
  A_52_P299446       U90654                                              up           **2.18**                                         *0.044*                                                        zinc-finger domain-containing protein
  A_52_P569327       AK045953                                            up           **2.16**                                         *0.044*                                    ***Usp53***         mKIAA1350, ubiquitin specific peptidase 53
  A_52_P208213       TC1638459                                           up           **2.15**                                         *0.044*                                                        kalirin-12a, partial (6%)
  A_51_P503494       NM_018790                                           up           **2.08**                                         *0.049*                                    ***Arc***           activity regulated cytoskeletal-associated protein
  A_52_P562661       NM_010762                                           up           **2.06**                                         *0.044*                                    ***Mal***           myelin and lymphocyte protein, T-cell differentiation protein
  A_51_P491987       NM_019955                                           up           **2.04**                                         *0.044*                                    ***Ripk3***         receptor-interacting serine-threonine kinase 3
  A_51_P499071       NM_010762                                           up           **2.04**                                         *0.044*                                    ***Mal***           myelin and lymphocyte protein, T-cell differentiation protein
  A_51_P506417       NM_016958                                           up           **2.03**                                         *0.044*                                    ***Krt14***         keratin 14
  A_51_P181565       NM_010415                                           up           **2.02**                                         *0.044*                                    ***Hbegf***         heparin-binding EGF-like growth factor
  A_51_P371500       BC049570                                            up           **2.00**                                         *0.044*                                    ***Atp8b3***        ATPase, class I, type 8B, member 3
  A_51_P426055       AK048117                                            down         **3.76**                                         *0.013*                                                        RIKEN full-length enriched library, clone:C130035O18, unclassifiable product
  A_52_P506984       ENSMUST00000044976[4](#TFN6){ref-type="table-fn"}   down         **3.22**                                         *0.044*                                    ***Glyat***         glycine-N-acyltransferase
  A_52_P707475       AK053952                                            down         **2.53**                                         *0.044*                                                        RIKEN full-length enriched library, clone:E230006P11, unclassifiable product
  A_52_P739568       AK082480                                            down         **2.17**                                         *0.044*                                                        RIKEN full-length enriched library, clone:C230053P15, unclassifiable product
  A_52_P101443       NM_198111                                           down         **2.14**                                         *0.044*                                    ***Akap6***         A kinase (PRKA) anchor protein 6

Compared to expression in normal mucosa

Student's t-test (two-tailed, unpaired, asymptotic), Benjamini-Hochberg multiple testing correction
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